Compare ENVA & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ENVA | NAMS |
|---|---|---|
| Founded | 2011 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | 100 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.5B |
| IPO Year | 2011 | N/A |
| Metric | ENVA | NAMS |
|---|---|---|
| Price | $168.41 | $31.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $173.00 | $46.75 |
| AVG Volume (30 Days) | 168.8K | ★ 811.6K |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.05 | N/A |
| EPS | ★ 11.52 | N/A |
| Revenue | ★ $3,151,653,000.00 | N/A |
| Revenue This Year | $149.64 | $17.96 |
| Revenue Next Year | $16.42 | $540.65 |
| P/E Ratio | $14.59 | ★ N/A |
| Revenue Growth | ★ 18.58 | N/A |
| 52 Week Low | $89.00 | $16.79 |
| 52 Week High | $176.68 | $42.00 |
| Indicator | ENVA | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 76.71 | 44.41 |
| Support Level | $153.44 | $29.73 |
| Resistance Level | $176.68 | $31.72 |
| Average True Range (ATR) | 4.47 | 1.68 |
| MACD | 2.66 | -0.28 |
| Stochastic Oscillator | 90.66 | 4.05 |
Enova International Inc provides online financial services, including short-term consumer loans, line of credit accounts, and installment loans to customers mainly in the United States and Brazil. Consumers apply for credit online, the company's technology platforms process the applications, and transactions are completed quickly and efficiently. Its customers are predominantly retail consumers and small businesses. Enova markets its financing products under the names CashNetUSA, NetCredit, OnDeck, Headway Capital, and Simplic. The company also operates a money transfer platform under the name Pangea. Geographically, the company generates a majority of its revenue from its business in the United States and the rest from other international countries.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.